Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Partial cure of chronic hepatitis B: potential implications for HCC surveillance?

Gut·2025
Same author

Development and Testing of the Protocol Quality Rating Tool (PQRT) to Evaluate Clinical Trial Protocol Document Quality.

Clinical and translational science·2025
Same author

Accurate identification and risk-stratification of HBeAg-negative indeterminate phase of chronic hepatitis B: Not all shades of grey are the same.

Hepatology (Baltimore, Md.)·2025
Same author

Accurate prediction of HCC risk in patients with chronic HBV infection: HBeAg status and HBsAg level matter.

Hepatology (Baltimore, Md.)·2025
Same author

Safety and efficacy of a defined bacterial consortium, VE303, to treat HE.

Hepatology communications·2025
Same author

Quest for HBV functional cure: what have we learnt from silencing RNAs?

Gut·2024
Same journal

Biliary Stent Placement by Endoscopic Retrograde Cholangiopancreatography: Quality Indicators and Technical Applications.

Gut and liver·2026
Same journal

Efficacy and Long-Term Outcomes of Direct-Acting Antivirals in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Gut and liver·2026
Same journal

Global, Regional, and National Burden of Liver Cancer from 1990 to 2021 and Projections to 2050: A Global Burden of Disease Study 2021.

Gut and liver·2026
Same journal

Sex and Gender Differences in Peptic Ulcer Disease: A Scoping Review with Exploratory Quantitative Synthesis for Clinical Guideline Development.

Gut and liver·2026
Same journal

Proteomic Analysis of Extracellular Vesicles Reveals Vitronectin and Laminin Subunit Alpha-3 as Candidate Biomarkers for Gastric Cancer.

Gut and liver·2026
Same journal

Clinical Outcomes of Endoscopic Resection for Gastric and Duodenal Neuroendocrine Tumors.

Gut and liver·2026
查看所有相关文章

相关实验视频

Updated: Jul 6, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.2K

实现B型肝炎的功能性治疗方法

Anna S F Lok1

  • 1Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA.

Gut and liver
|March 27, 2024
PubMed
概括
此摘要是机器生成的。

实现慢性乙型肝炎病毒 (HBV) 感染的功能治疗需要新的治疗方法. 直接作用抗病毒药物和免疫调节剂的组合,特别是基化干扰素-α (pegIFN-α),对HBsAg损失有希望.

关键词:
直接作用的抗病毒药物.乙型肝炎的表面抗原损失.免疫调节疗法 免疫调节疗法核化物类似物化干扰素-α的使用.

更多相关视频

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.9K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K

相关实验视频

Last Updated: Jul 6, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.2K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.9K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K

科学领域:

  • 肝病学 肝病学是一种肝病学.
  • 病毒学 病毒学
  • 免疫学 免疫学 免疫学

背景情况:

  • 目前的慢性乙型肝炎病毒 (HBV) 治疗抑制了复制,但很少达到乙型肝炎表面抗原 (HBsAg) 损失.
  • 功能性HBV治愈需要在有限治疗后无法检测到的HBsAg和HBVDNA,以及恢复的免疫反应.

研究的目的:

  • 审查开发功能性HBV治愈有限疗法的进展和挑战.
  • 评估单独和组合的新型直接作用抗病毒药物和免疫调节疗法的潜力.

主要方法:

  • 对直接作用抗病毒药物 (DAA) 和免疫调节疗法的临床试验数据的分析.
  • 专注于组合疗法,特别是那些涉及基化干扰素-α (pegIFN-α) 的疗法.

主要成果:

  • 单独使用DAA和免疫调节疗法无法治愈HBV.
  • 最近的组合试验,特别是包括pegIFN-α在内的试验,显示出有前途的结果,以实现功能治愈.
  • 需要在更大规模的研究中进一步证实,随访时间更长.

结论:

  • 组合疗法是实现功能性HBV治愈的有希望的策略.
  • 开发更简单,更安全,口服治疗方案至关重要.
  • 安全性仍然至关重要,新疗法必须比长期的核胺模拟 (NA) 疗法提供明显的优势.